Abstract
Background
Fundic gland polyps (FGP) have been implicated with long-term proton pump inhibitor (PPI) use.
Aims
We attempted to investigate the impact of length and dosage of PPI therapy on the development of FGP.
Methods
A retrospective cohort study of all patients who had gastric polyps removed during elective upper endoscopy between March and September 2007 as part of a prior prospective study protocol was carried out. FGP were determined histologically. Prior to endoscopy, all patients completed a questionnaire regarding PPI use and length of therapy (no PPI use, 1–48 months, >48 months). The dosage of PPI was obtained via a thorough chart review of electronic medical records.
Results
Three hundred and eighty-five patients completed upper endoscopy and a questionnaire reporting PPI use (252 [65.4%] patients on PPI). On endoscopy, 55 patients had polyps, with the majority (43/55, 78%) being FGP, resulting in an overall prevalence of 11.1% (43/385). On univariate analysis, FGP were associated with Caucasian race (15 vs. 6%; P = 0.009) and chronic PPI therapy (>48 months) (31.9 vs. 7.5%, P < 0.001). There was a significant linear-by-linear association between PPI dosage and FGP prevalence (no PPI use, 7.5%; once daily, 10.8%; twice daily 17.4%, P = 0.026). On logistic regression, the only independent predictor of FGP was duration of PPI use >48 months (P = 0.001, odds ratio [OR] 4.7 [2.0–12.9]).
Conclusions
The only independent predictor of FGP development in our study was duration of PPI therapy greater than 48 months. Increased dosage of therapy did not significantly impact the development of FGP.
Similar content being viewed by others
References
Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol. 2008;14:1318–1320.
Raghunath AS, O’Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005;22(Suppl 1):55–63.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955–1960.
Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953.
Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies. CMAJ. 2004;171:33–38.
Van Vlierberghe H, De Vos M, De Cock G, Cuvelier C, Elewaut A. Fundic gland polyps: three other case reports suggesting a possible association with acid suppressing therapy. Acta Gastroenterol Belg. 1997;60:240–242.
Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust. 1992;157:287–288.
el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol. 1997;92:1858–1860.
Choudhry U, Boyce HW Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol. 1998;110:615–621.
Jalving M, Koornstra JJ, Wesseling J, Boezen HM, de Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther. 2006;24:1341–1348.
Burt RW. Gastric fundic gland polyps. Gastroenterology. 2003;125:1462–1469.
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000;157:747–754.
Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol. 2009;104:1524–1532.
Marcial MA, Villafaña M, Hernandez-Denton J, Colon-Pagan JR. Fundic gland polyps: prevalence and clinicopathologic features. Am J Gastroenterol. 1993;88:1711–1713.
Torbenson M, Lee JH, Cruz-Correa M, Ravich W, Rastgar K, Abraham SC, Wu TT. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol. 2002;15:718–723.
Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158:1005–1010.
Domizio P, Talbot IC, Spigelman AD, Williams CB, Phillips RK. Upper gastrointestinal pathology in familial adenomatous polyposis: results from a prospective study of 102 patients. J Clin Pathol. 1990;43:738–743.
Goodman AJ, Dundas SA, Scholefield JH, Johnson BF. Gastric carcinoma and familial adenomatous polyposis (FAP). Int J Colorectal Dis. 1988;3:201–203.
Jalving M, Koornstra JJ, Boersma-van Ek W, de Jong S, Karrenbeld A, Hollema H, de Vries EG, Kleibeuker JH. Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol. 2003;38:916–922.
Stolte M, Vieth M, Ebert MP. High-grade dysplasia in sporadic fundic gland polyps: clinically relevant or not? Eur J Gastroenterol Hepatol. 2003;15:1153–1156.
Vieth M, Stolte M. Fundic gland polyps are not induced by proton pump inhibitor therapy. Am J Clin Pathol. 2001;116:716–720.
Fossmark R, Jianu CS, Martinsen TC, Qvigstad G, Syversen U, Waldum HL. Serum gastrin and chromogranin a levels in patients with fundic gland polyps caused by long-term proton-pump inhibition. Scand J Gastroenterol. 2008;43:20–24.
Masaoka T, Suzuki H, Hibi T. Gastric epithelial cell modality and proton pump inhibitor. J Clin Biochem Nutr. 2008;42:191–196.
Koh TJ, Chen D. Gastrin as a growth factor in the gastrointestinal tract. Regul Pept. 2000;93:37–44.
Synnerstad I, Holm L. Omeprazole induces high intraglandular pressure in the rat gastric mucosa. Gastroenterology. 1997;112:1221–1230.
Cats A, Schenk BE, Bloemena E, Roosedaal R, Lindeman J, Biemond I, Klinkenberg-Knol EC, Meuwissen SG, Kuipers EJ. Parietal cell protrusions and fundic gland cysts during omeprazole maintenance treatment. Hum Pathol. 2000;31:684–690.
Krishnamurthy S, Dayal Y. Parietal cell protrusions in gastric ulcer disease. Hum Pathol. 1997;28:1126–1130.
Watanabe N, Seno H, Nakajima T, Yazumi S, Miyamoto S, Matsumoto S, Itoh T, Kawanami C, Okazaki K, Chiba T. Regression of fundic gland polyps following acquisition of Helicobacter pylori. Gut. 2002;51:742–745.
Iida M, Yao T, Watanabe H, Imamura K, Fuyuno S, Omae T. Spontaneous disappearance of fundic gland polyposis: report of three cases. Gastroenterology. 1980;79:725–728.
Sekine S, Shibata T, Yamauchi Y, Nakanishi Y, Shimoda T, Sakamoto M, Hirohashi S. Beta-catenin mutations in sporadic fundic gland polyps. Virchows Arch. 2002;440:381–386.
Hofgärtner WT, Thorp M, Ramus MW, Delorefice G, Chey WY, Ryan CK, Takahashi GW, Lobitz JR. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol. 1999;94:2275–2281.
Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep. 2008;10:543–547.
Attard TM, Yardley JH, Cuffari C. Gastric polyps in pediatrics: an 18-year hospital-based analysis. Am J Gastroenterol. 2002;97:298–301.
Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, Spirio L, Chey WY. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology. 1997;113:659–663.
Abraham SC, Park SJ, Mugartegui L, Hamilton SR, Wu TT. Sporadic fundic gland polyps with epithelial dysplasia: evidence for preferential targeting for mutations in the adenomatous polyposis coli gene. Am J Pathol. 2002;161:1735–1742.
Jalving M, Koornstra JJ, Götz JM, van der Waaij LA, de Jong S, Zwart N, Karrenbeld A, Kleibeuker JH. High-grade dysplasia in sporadic fundic gland polyps: a case report and review of the literature. Eur J Gastroenterol Hepatol. 2003;15:1229–1233.
Author information
Authors and Affiliations
Corresponding author
Additional information
Disclosure: The opinions in this paper are solely those of the authors and do not represent an endorsement by the Department of Defense. This is a U.S. Government work. There are no restrictions on its use. There are no conflicts of interest, financial disclosures, grant support, or writing assistance.
Rights and permissions
About this article
Cite this article
Ally, M.R., Veerappan, G.R., Maydonovitch, C.L. et al. Chronic Proton Pump Inhibitor Therapy Associated with Increased Development of Fundic Gland Polyps. Dig Dis Sci 54, 2617–2622 (2009). https://doi.org/10.1007/s10620-009-0993-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-009-0993-z